title: [Protecting infection by using rhG-CSF in patients with lung cancer during chemotherapeutic courses].
abstract: OBJECTIVE
  To recognize the prophylactic effect of rhG-CSF used on infection complications secondary to chemotherapy in patients with lung cancer.
  
  
  METHODS
  The infection complications and the neutropenia secondary to chemotherapy in 163 cases of lung cancer patients with or without rhG-CSF were retrospectively analyzed.
  
  
  RESULTS
  Rhg-CSF administration reduced the frequency of infection complications, and there was a significant difference(P < 0.005) in the frequency of infection between the G-CSF group's patients (infections incidence 25%) and non-G-CSF group's (56%). The incidence of neutropenia in G-CSF group' patients is obviously less than that in non-G-CSF group's (P < 0.005). The median number of days of the neutropenia (neutrophil count of < 1.0 x 10(9) in G-CSF group(3 days) is less than that in non-G-CSF group(4 days)(P < 0.001). However, there was no significant difference (P > 0.05) between G-CSF group(63%) and non-G-CSF group(76%) in terms of response of the infection complications.
  
  
  CONCLUSIONS
  Our data has shown that the administration of rhG-CSF as an adjunct to chemotherapy in patients with lung cancer can accelerate neutrophil recovery and shorten the duration of neutropenia, and lead to reductions in the incidence of infection complications, and also has the potential to increase the amount of cytotoxic chemotherapy and the quantity of life.
authors.affiliation: School of Oncology, Beijing Medical University, Beijing, 100036.
authors.forename: S
authors.initials: S
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Fang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D011994:Recombinant Proteins; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor